@article{Davis2021b,
abstract = {Background: Tuberculous meningitis (TBM) is the most lethal form of tuberculosis with a mortality of {\~{}}50{\%} in those co-infected with HIV-1. Current antibiotic regimens are based on those known to be effective in pulmonary TB and do not account for the differing ability of the drugs to penetrate the central nervous system (CNS). The host immune response drives pathology in TBM, yet effective host-directed therapies are scarce. There is sufficient data to suggest that higher doses of rifampicin (RIF), additional linezolid (LZD) and adjunctive aspirin (ASA) will be beneficial in TBM yet rigorous investigation of the safety of these interventions in the context of HIV associated TBM is required. We hypothesise that increased dose RIF, LZD and ASA used in combination and in addition to standard of care for the first 56 days of treatment with be safe and tolerated in HIV-1 infected people with TBM.},
author = {Davis, Angharad G and Wasserman, Sean and Maxebengula, Mpumi and Stek, Cari and Bremer, Marise and Daroowala, Remy and Aziz, Saalikha and Goliath, Rene and Stegmann, Stephani and Koekemoer, Sonya and Jackson, Amanda and {Lai Sai}, Louise and Kadernani, Yakub and Sihoyiya, Thandi and Liang, C.Jason and Dodd, Lori and Denti, Paolo and Crede, Thomas and Naude, Jonathan and Szymanski, Patryk and Vallie, Yakoob and Banderker, Ismail and Moosa, Shiraz and Raubenheimer, Peter and Lai, Rachel P J and Joska, John and Nightingale, Sam and Dreyer, Anna and Wahl, Gerda and Offiah, Curtis and Vorster, Isak and Candy, Sally and Robertson, Frances and Meintjes, Ernesta and Maartens, Gary and Black, John and Meintjes, Graeme and Wilkinson, Robert J},
doi = {10.12688/wellcomeopenres.16783.1},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Davis et al. - 2021 - Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive lin.pdf:pdf;:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Davis et al. - 2021 - Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive (2).pdf:pdf},
issn = {2398-502X},
journal = {Wellcome Open Research},
keywords = {Aspirin,HIV,Linezolid,OA,OA{\_}PMC,Rifampicin,Tuberculous meningitis,fund{\_}ack,protocol},
mendeley-tags = {OA,OA{\_}PMC,fund{\_}ack,protocol},
month = {jun},
pages = {136},
pmid = {34286103},
publisher = {F1000 Research Limited},
title = {{Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM] [version 1; peer review: 2 approved]}},
url = {https://wellcomeopenresearch.org/articles/6-136/v1},
volume = {6},
year = {2021}
}

{"_id":"Le7PDMEKng86AGsAo","bibbaseid":"davis-wasserman-maxebengula-stek-bremer-daroowala-aziz-goliath-etal-studyprotocolforaphase2atrialofthesafetyandtolerabilityofincreaseddoserifampicinandadjunctivelinezolidwithorwithoutaspirinforhivassociatedtuberculousmeningitislasertbmversion1peerreview2approved-2021","author_short":["Davis, A. G","Wasserman, S.","Maxebengula, M.","Stek, C.","Bremer, M.","Daroowala, R.","Aziz, S.","Goliath, R.","Stegmann, S.","Koekemoer, S.","Jackson, A.","Lai Sai, L.","Kadernani, Y.","Sihoyiya, T.","Liang, C.","Dodd, L.","Denti, P.","Crede, T.","Naude, J.","Szymanski, P.","Vallie, Y.","Banderker, I.","Moosa, S.","Raubenheimer, P.","Lai, R. P J","Joska, J.","Nightingale, S.","Dreyer, A.","Wahl, G.","Offiah, C.","Vorster, I.","Candy, S.","Robertson, F.","Meintjes, E.","Maartens, G.","Black, J.","Meintjes, G.","Wilkinson, R. J"],"bibdata":{"bibtype":"article","type":"article","abstract":"Background: Tuberculous meningitis (TBM) is the most lethal form of tuberculosis with a mortality of \\ 50% in those co-infected with HIV-1. Current antibiotic regimens are based on those known to be effective in pulmonary TB and do not account for the differing ability of the drugs to penetrate the central nervous system (CNS). The host immune response drives pathology in TBM, yet effective host-directed therapies are scarce. There is sufficient data to suggest that higher doses of rifampicin (RIF), additional linezolid (LZD) and adjunctive aspirin (ASA) will be beneficial in TBM yet rigorous investigation of the safety of these interventions in the context of HIV associated TBM is required. We hypothesise that increased dose RIF, LZD and ASA used in combination and in addition to standard of care for the first 56 days of treatment with be safe and tolerated in HIV-1 infected people with TBM.","author":[{"propositions":[],"lastnames":["Davis"],"firstnames":["Angharad","G"],"suffixes":[]},{"propositions":[],"lastnames":["Wasserman"],"firstnames":["Sean"],"suffixes":[]},{"propositions":[],"lastnames":["Maxebengula"],"firstnames":["Mpumi"],"suffixes":[]},{"propositions":[],"lastnames":["Stek"],"firstnames":["Cari"],"suffixes":[]},{"propositions":[],"lastnames":["Bremer"],"firstnames":["Marise"],"suffixes":[]},{"propositions":[],"lastnames":["Daroowala"],"firstnames":["Remy"],"suffixes":[]},{"propositions":[],"lastnames":["Aziz"],"firstnames":["Saalikha"],"suffixes":[]},{"propositions":[],"lastnames":["Goliath"],"firstnames":["Rene"],"suffixes":[]},{"propositions":[],"lastnames":["Stegmann"],"firstnames":["Stephani"],"suffixes":[]},{"propositions":[],"lastnames":["Koekemoer"],"firstnames":["Sonya"],"suffixes":[]},{"propositions":[],"lastnames":["Jackson"],"firstnames":["Amanda"],"suffixes":[]},{"propositions":[],"lastnames":["Lai Sai"],"firstnames":["Louise"],"suffixes":[]},{"propositions":[],"lastnames":["Kadernani"],"firstnames":["Yakub"],"suffixes":[]},{"propositions":[],"lastnames":["Sihoyiya"],"firstnames":["Thandi"],"suffixes":[]},{"propositions":[],"lastnames":["Liang"],"firstnames":["C.Jason"],"suffixes":[]},{"propositions":[],"lastnames":["Dodd"],"firstnames":["Lori"],"suffixes":[]},{"propositions":[],"lastnames":["Denti"],"firstnames":["Paolo"],"suffixes":[]},{"propositions":[],"lastnames":["Crede"],"firstnames":["Thomas"],"suffixes":[]},{"propositions":[],"lastnames":["Naude"],"firstnames":["Jonathan"],"suffixes":[]},{"propositions":[],"lastnames":["Szymanski"],"firstnames":["Patryk"],"suffixes":[]},{"propositions":[],"lastnames":["Vallie"],"firstnames":["Yakoob"],"suffixes":[]},{"propositions":[],"lastnames":["Banderker"],"firstnames":["Ismail"],"suffixes":[]},{"propositions":[],"lastnames":["Moosa"],"firstnames":["Shiraz"],"suffixes":[]},{"propositions":[],"lastnames":["Raubenheimer"],"firstnames":["Peter"],"suffixes":[]},{"propositions":[],"lastnames":["Lai"],"firstnames":["Rachel","P","J"],"suffixes":[]},{"propositions":[],"lastnames":["Joska"],"firstnames":["John"],"suffixes":[]},{"propositions":[],"lastnames":["Nightingale"],"firstnames":["Sam"],"suffixes":[]},{"propositions":[],"lastnames":["Dreyer"],"firstnames":["Anna"],"suffixes":[]},{"propositions":[],"lastnames":["Wahl"],"firstnames":["Gerda"],"suffixes":[]},{"propositions":[],"lastnames":["Offiah"],"firstnames":["Curtis"],"suffixes":[]},{"propositions":[],"lastnames":["Vorster"],"firstnames":["Isak"],"suffixes":[]},{"propositions":[],"lastnames":["Candy"],"firstnames":["Sally"],"suffixes":[]},{"propositions":[],"lastnames":["Robertson"],"firstnames":["Frances"],"suffixes":[]},{"propositions":[],"lastnames":["Meintjes"],"firstnames":["Ernesta"],"suffixes":[]},{"propositions":[],"lastnames":["Maartens"],"firstnames":["Gary"],"suffixes":[]},{"propositions":[],"lastnames":["Black"],"firstnames":["John"],"suffixes":[]},{"propositions":[],"lastnames":["Meintjes"],"firstnames":["Graeme"],"suffixes":[]},{"propositions":[],"lastnames":["Wilkinson"],"firstnames":["Robert","J"],"suffixes":[]}],"doi":"10.12688/wellcomeopenres.16783.1","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Davis et al. - 2021 - Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive lin.pdf:pdf;:C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Davis et al. - 2021 - Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive (2).pdf:pdf","issn":"2398-502X","journal":"Wellcome Open Research","keywords":"Aspirin,HIV,Linezolid,OA,OA_PMC,Rifampicin,Tuberculous meningitis,fund_ack,protocol","mendeley-tags":"OA,OA_PMC,fund_ack,protocol","month":"jun","pages":"136","pmid":"34286103","publisher":"F1000 Research Limited","title":"Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM] [version 1; peer review: 2 approved]","url":"https://wellcomeopenresearch.org/articles/6-136/v1","volume":"6","year":"2021","bibtex":"@article{Davis2021b,\r\nabstract = {Background: Tuberculous meningitis (TBM) is the most lethal form of tuberculosis with a mortality of {\\~{}}50{\\%} in those co-infected with HIV-1. Current antibiotic regimens are based on those known to be effective in pulmonary TB and do not account for the differing ability of the drugs to penetrate the central nervous system (CNS). The host immune response drives pathology in TBM, yet effective host-directed therapies are scarce. There is sufficient data to suggest that higher doses of rifampicin (RIF), additional linezolid (LZD) and adjunctive aspirin (ASA) will be beneficial in TBM yet rigorous investigation of the safety of these interventions in the context of HIV associated TBM is required. We hypothesise that increased dose RIF, LZD and ASA used in combination and in addition to standard of care for the first 56 days of treatment with be safe and tolerated in HIV-1 infected people with TBM.},\r\nauthor = {Davis, Angharad G and Wasserman, Sean and Maxebengula, Mpumi and Stek, Cari and Bremer, Marise and Daroowala, Remy and Aziz, Saalikha and Goliath, Rene and Stegmann, Stephani and Koekemoer, Sonya and Jackson, Amanda and {Lai Sai}, Louise and Kadernani, Yakub and Sihoyiya, Thandi and Liang, C.Jason and Dodd, Lori and Denti, Paolo and Crede, Thomas and Naude, Jonathan and Szymanski, Patryk and Vallie, Yakoob and Banderker, Ismail and Moosa, Shiraz and Raubenheimer, Peter and Lai, Rachel P J and Joska, John and Nightingale, Sam and Dreyer, Anna and Wahl, Gerda and Offiah, Curtis and Vorster, Isak and Candy, Sally and Robertson, Frances and Meintjes, Ernesta and Maartens, Gary and Black, John and Meintjes, Graeme and Wilkinson, Robert J},\r\ndoi = {10.12688/wellcomeopenres.16783.1},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Davis et al. - 2021 - Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive lin.pdf:pdf;:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Davis et al. - 2021 - Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive (2).pdf:pdf},\r\nissn = {2398-502X},\r\njournal = {Wellcome Open Research},\r\nkeywords = {Aspirin,HIV,Linezolid,OA,OA{\\_}PMC,Rifampicin,Tuberculous meningitis,fund{\\_}ack,protocol},\r\nmendeley-tags = {OA,OA{\\_}PMC,fund{\\_}ack,protocol},\r\nmonth = {jun},\r\npages = {136},\r\npmid = {34286103},\r\npublisher = {F1000 Research Limited},\r\ntitle = {{Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM] [version 1; peer review: 2 approved]}},\r\nurl = {https://wellcomeopenresearch.org/articles/6-136/v1},\r\nvolume = {6},\r\nyear = {2021}\r\n}\r\n","author_short":["Davis, A. G","Wasserman, S.","Maxebengula, M.","Stek, C.","Bremer, M.","Daroowala, R.","Aziz, S.","Goliath, R.","Stegmann, S.","Koekemoer, S.","Jackson, A.","Lai Sai, L.","Kadernani, Y.","Sihoyiya, T.","Liang, C.","Dodd, L.","Denti, P.","Crede, T.","Naude, J.","Szymanski, P.","Vallie, Y.","Banderker, I.","Moosa, S.","Raubenheimer, P.","Lai, R. P J","Joska, J.","Nightingale, S.","Dreyer, A.","Wahl, G.","Offiah, C.","Vorster, I.","Candy, S.","Robertson, F.","Meintjes, E.","Maartens, G.","Black, J.","Meintjes, G.","Wilkinson, R. J"],"key":"Davis2021b","id":"Davis2021b","bibbaseid":"davis-wasserman-maxebengula-stek-bremer-daroowala-aziz-goliath-etal-studyprotocolforaphase2atrialofthesafetyandtolerabilityofincreaseddoserifampicinandadjunctivelinezolidwithorwithoutaspirinforhivassociatedtuberculousmeningitislasertbmversion1peerreview2approved-2021","role":"author","urls":{"Paper":"https://wellcomeopenresearch.org/articles/6-136/v1"},"keyword":["Aspirin","HIV","Linezolid","OA","OA_PMC","Rifampicin","Tuberculous meningitis","fund_ack","protocol"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh"],"keywords":["aspirin","hiv","linezolid","oa","oa_pmc","rifampicin","tuberculous meningitis","fund_ack","protocol"],"search_terms":["study","protocol","phase","trial","safety","tolerability","increased","dose","rifampicin","adjunctive","linezolid","without","aspirin","hiv","associated","tuberculous","meningitis","laser","tbm","version","peer","review","approved","davis","wasserman","maxebengula","stek","bremer","daroowala","aziz","goliath","stegmann","koekemoer","jackson","lai sai","kadernani","sihoyiya","liang","dodd","denti","crede","naude","szymanski","vallie","banderker","moosa","raubenheimer","lai","joska","nightingale","dreyer","wahl","offiah","vorster","candy","robertson","meintjes","maartens","black","meintjes","wilkinson"],"title":"Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM] [version 1; peer review: 2 approved]","year":2021}